{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:21:46Z","timestamp":1790749306835,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T00:00:00Z","timestamp":1462752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital Universitario Ram\u00f3n y Cajal"},{"name":"GW Pharmaceuticals Ltd."},{"DOI":"10.13039\/501100006541","name":"Consejer\u00eda de Sanidad, Comunidad de Madrid","doi-asserted-by":"publisher","award":["S2010\/BMD-2308"],"award-info":[{"award-number":["S2010\/BMD-2308"]}],"id":[{"id":"10.13039\/501100006541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s00415-016-8145-9","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T01:11:54Z","timestamp":1462756314000},"page":"1390-1400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease"],"prefix":"10.1007","volume":"263","author":[{"given":"Jose Luis","family":"L\u00f3pez-Send\u00f3n Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Garc\u00eda Caldentey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Trigo Cubillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Ruiz Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garc\u00eda Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A. Alonso","family":"Alonso Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Garc\u00eda de Y\u00e9benes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Mar\u00eda","family":"Tol\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Galve-Roperh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onintza","family":"Sagredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Valdeolivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Resel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ortega-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Laura","family":"Garc\u00eda-Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Fern\u00e1ndez Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justo","family":"Garc\u00eda de Y\u00e9benes Prous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,9]]},"reference":[{"issue":"9557","key":"8145_CR1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker FO (2007) Huntington\u2019s disease. Lancet 369(9557):218\u2013228","journal-title":"Lancet"},{"issue":"6","key":"8145_CR2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72(6):971\u2013983","journal-title":"Cell"},{"issue":"Pt 4","key":"8145_CR3","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/brain\/awn025","volume":"131","author":"HD Rosas","year":"2008","unstructured":"Rosas HD, Salat DH, Lee SY et al (2008) Cerebral cortex and the clinical expression of Huntington\u2019s disease: complexity and heterogeneity. Brain 131(Pt 4):1057\u20131068","journal-title":"Brain"},{"issue":"5642","key":"8145_CR4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1088208","volume":"302","author":"G Marsicano","year":"2003","unstructured":"Marsicano G, Goodenough S, Monory K et al (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302(5642):84\u201388","journal-title":"Science"},{"issue":"7","key":"8145_CR5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/dmrr.764","volume":"23","author":"D Cota","year":"2007","unstructured":"Cota D (2007) CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 23(7):507\u2013517","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"8145_CR6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1152\/physrev.00019.2008","volume":"89","author":"M Kano","year":"2009","unstructured":"Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89(1):309\u2013380","journal-title":"Physiol Rev"},{"issue":"1","key":"8145_CR7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12035-007-0003-4","volume":"36","author":"S Wright","year":"2007","unstructured":"Wright S (2007) Cannabinoid-based medicines for neurological disorders\u2013clinical evidence. Mol Neurobiol 36(1):129\u2013136","journal-title":"Mol Neurobiol"},{"issue":"7","key":"8145_CR8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1476-5381.2008.00088.x","volume":"156","author":"J Fernandez-Ruiz","year":"2009","unstructured":"Fernandez-Ruiz J (2009) The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 156(7):1029\u20131040","journal-title":"Br J Pharmacol"},{"issue":"23","key":"8145_CR9","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2174\/138161208785740108","volume":"14","author":"MR Pazos","year":"2008","unstructured":"Pazos MR, Sagredo O, Fernandez-Ruiz J (2008) The endocannabinoid system in Huntington\u2019s disease. Curr Pharm Des 14(23):2317\u20132325","journal-title":"Curr Pharm Des"},{"issue":"1","key":"8145_CR10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tips.2006.11.001","volume":"28","author":"J Fernandez-Ruiz","year":"2007","unstructured":"Fernandez-Ruiz J, Romero J, Velasco G, Tolon RM, Ramos JA, Guzman M (2007) Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 28(1):39\u201345","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"8145_CR11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1517\/14728221003709792","volume":"14","author":"J Fernandez-Ruiz","year":"2010","unstructured":"Fernandez-Ruiz J, Garcia C, Sagredo O, Gomez-Ruiz M, de Lago E (2010) The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 14(4):387\u2013404","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"8145_CR12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1476-5381.2008.00048.x","volume":"156","author":"RG Pertwee","year":"2009","unstructured":"Pertwee RG (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156(3):397\u2013411","journal-title":"Br J Pharmacol"},{"issue":"6","key":"8145_CR13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1755-5949.2010.00195.x","volume":"17","author":"A Gowran","year":"2011","unstructured":"Gowran A, Noonan J, Campbell VA (2011) The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci Ther 17(6):637\u2013644","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"8145_CR14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.26142","volume":"30","author":"B Kluger","year":"2015","unstructured":"Kluger B, Triolo P, Jones W, Jankovic J (2015) The therapeutic potential of cannabinoids for movement disorders. Mov Disord 30(3):313\u2013327","journal-title":"Mov Disord"},{"issue":"2","key":"8145_CR15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","volume":"11","author":"M Herkenham","year":"1991","unstructured":"Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11(2):563\u2013583","journal-title":"J Neurosci"},{"issue":"1","key":"8145_CR16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.neuroscience.2007.10.029","volume":"151","author":"E Nunez","year":"2008","unstructured":"Nunez E, Benito C, Tolon RM, Hillard CJ, Griffin WS, Romero J (2008) Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down\u2019s syndrome. Neuroscience 151(1):104\u2013110","journal-title":"Neuroscience"},{"key":"8145_CR17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0083-6729(09)81015-7","volume":"81","author":"A Toth","year":"2009","unstructured":"Toth A, Blumberg PM, Boczan J (2009) Anandamide and the vanilloid receptor (TRPV1). Vitam Horm 81:389\u2013419","journal-title":"Vitam Horm"},{"issue":"2\u20133","key":"8145_CR18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1385\/MN:26:2-3:317","volume":"26","author":"M Stelt van der","year":"2002","unstructured":"van der Stelt M, Veldhuis WB, Maccarrone M et al (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26(2\u20133):317\u2013346","journal-title":"Mol Neurobiol"},{"issue":"22","key":"8145_CR19","doi-asserted-by":"crossref","first-page":"8257","DOI":"10.1073\/pnas.1400988111","volume":"111","author":"A Chiarlone","year":"2014","unstructured":"Chiarlone A, Bellocchio L, Blazquez C et al (2014) A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci USA 111(22):8257\u20138262","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Pt 11","key":"8145_CR20","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","volume":"132","author":"J Palazuelos","year":"2009","unstructured":"Palazuelos J, Aguado T, Pazos MR et al (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity. Brain 132(Pt 11):3152\u20133164","journal-title":"Brain"},{"issue":"14","key":"8145_CR21","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1073\/pnas.95.14.8268","volume":"95","author":"AJ Hampson","year":"1998","unstructured":"Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95(14):8268\u20138273","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"8145_CR22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/1531-8257(199911)14:6<1038::AID-MDS1024>3.0.CO;2-7","volume":"14","author":"KR Muller-Vahl","year":"1999","unstructured":"Muller-Vahl KR, Schneider U, Emrich HM (1999) Nabilone increases choreatic movements in Huntington\u2019s disease. Mov Disord 14(6):1038\u20131040","journal-title":"Mov Disord"},{"issue":"4","key":"8145_CR23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1176\/jnp.2006.18.4.553","volume":"18","author":"A Curtis","year":"2006","unstructured":"Curtis A, Rickards H (2006) Nabilone could treat chorea and irritability in Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci 18(4):553\u2013554","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"15","key":"8145_CR24","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","volume":"24","author":"A Curtis","year":"2009","unstructured":"Curtis A, Mitchell I, Patel S, Ives N, Rickards H (2009) A pilot study using nabilone for symptomatic treatment in Huntington\u2019s disease. Mov Disord 24(15):2254\u20132259","journal-title":"Mov Disord"},{"issue":"3","key":"8145_CR25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","volume":"40","author":"P Consroe","year":"1991","unstructured":"Consroe P, Laguna J, Allender J et al (1991) Controlled clinical trial of cannabidiol in Huntington\u2019s disease. Pharmacol Biochem Behav 40(3):701\u2013708","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"8145_CR26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.mehy.2005.08.026","volume":"66","author":"E Russo","year":"2006","unstructured":"Russo E, Guy GW (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66(2):234\u2013246","journal-title":"Med Hypotheses"},{"issue":"15","key":"8145_CR27","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1097\/00001756-200410250-00015","volume":"15","author":"I Lastres-Becker","year":"2004","unstructured":"Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernandez-Ruiz J, Brouillet E (2004) Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. NeuroReport 15(15):2375\u20132379","journal-title":"NeuroReport"},{"issue":"4","key":"8145_CR28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1460-9568.2007.05717.x","volume":"26","author":"O Sagredo","year":"2007","unstructured":"Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernandez-Ruiz J (2007) Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 26(4):843\u2013851","journal-title":"Eur J Neurosci"},{"issue":"5","key":"8145_CR29","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/cn200114w","volume":"3","author":"S Valdeolivas","year":"2011","unstructured":"Valdeolivas S, Satta V, Pertwee RG, Fernandez-Ruiz J, Sagredo O (2011) Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington\u2019s disease: role of CB1 and CB2 receptors. ACS Chem Neurosci 3(5):400\u2013406","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"8145_CR30","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group (1996) Unified Huntington\u2019s Disease Rating Scale: reliability and consistency. Mov Disord 11(2):136\u2013142","journal-title":"Mov Disord"},{"issue":"9","key":"8145_CR31","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/archneur.60.9.1218","volume":"60","author":"E Gomez-Tortosa","year":"2003","unstructured":"Gomez-Tortosa E, Gonzalo I, Fanjul S et al (2003) Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol 60(9):1218\u20131222","journal-title":"Arch Neurol"},{"issue":"3","key":"8145_CR32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1471-4159.1989.tb11774.x","volume":"53","author":"J Reiriz","year":"1989","unstructured":"Reiriz J, Mena MA, Bazan E et al (1989) Temporal profile of levels of monoamines and their metabolites in striata of rats implanted with dialysis tubes. J Neurochem 53(3):789\u2013792","journal-title":"J Neurochem"},{"issue":"11","key":"8145_CR33","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/hmg\/ddr111","volume":"20","author":"PM Gaughwin","year":"2011","unstructured":"Gaughwin PM, Ciesla M, Lahiri N, Tabrizi SJ, Brundin P, Bjorkqvist M (2011) Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington\u2019s disease. Hum Mol Genet 20(11):2225\u20132237","journal-title":"Hum Mol Genet"},{"issue":"50","key":"8145_CR34","doi-asserted-by":"crossref","first-page":"13765","DOI":"10.1002\/anie.201407807","volume":"53","author":"G Hernandez-Torres","year":"2014","unstructured":"Hernandez-Torres G, Cipriano M, Heden E et al (2014) A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis. Angew Chem Int Ed Engl 53(50):13765\u201313770","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1\u20132","key":"8145_CR35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.neuint.2007.06.031","volume":"52","author":"T Bisogno","year":"2008","unstructured":"Bisogno T, Martire A, Petrosino S, Popoli P, Di Marzo V (2008) Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6\/2 mice, a transgenic model of Huntington\u2019s disease. Neurochem Int 52(1\u20132):307\u2013313","journal-title":"Neurochem Int"},{"issue":"2","key":"8145_CR36","doi-asserted-by":"crossref","first-page":"e90202","DOI":"10.1371\/journal.pone.0090202","volume":"9","author":"MA Fernandez-Estevez","year":"2014","unstructured":"Fernandez-Estevez MA, Casarejos MJ, Lopez Sendon J et al (2014) Trehalose reverses cell malfunction in fibroblasts from normal and Huntington\u2019s disease patients caused by proteosome inhibition. PLoS One 9(2):e90202","journal-title":"PLoS One"},{"issue":"1","key":"8145_CR37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nbd.2007.04.012","volume":"27","author":"N Battista","year":"2007","unstructured":"Battista N, Bari M, Tarditi A et al (2007) Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington\u2019s disease mutation in peripheral lymphocytes. Neurobiol Dis 27(1):108\u2013116","journal-title":"Neurobiol Dis"},{"issue":"3","key":"8145_CR38","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-130050","volume":"35","author":"MJ Casarejos","year":"2013","unstructured":"Casarejos MJ, Perucho J, Gomez A et al (2013) Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis 35(3):525\u2013539","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"8145_CR39","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, Alafuzoff I, Herukka SK et al (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3):382\u2013389","journal-title":"Arch Neurol"},{"issue":"5","key":"8145_CR40","doi-asserted-by":"crossref","first-page":"e64037","DOI":"10.1371\/journal.pone.0064037","volume":"8","author":"C Giampa","year":"2013","unstructured":"Giampa C, Montagna E, Dato C, Melone MA, Bernardi G, Fusco FR (2013) Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6\/2 mouse model of Huntington\u2019s disease. PLoS One 8(5):e64037","journal-title":"PLoS One"},{"issue":"5529","key":"8145_CR41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","volume":"293","author":"C Zuccato","year":"2001","unstructured":"Zuccato C, Ciammola A, Rigamonti D et al (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science 293(5529):493\u2013498","journal-title":"Science"},{"issue":"9","key":"8145_CR42","doi-asserted-by":"crossref","first-page":"e46492","DOI":"10.1371\/journal.pone.0046492","volume":"7","author":"KH Chang","year":"2012","unstructured":"Chang KH, Chen YC, Wu YR, Lee WF, Chen CM (2012) Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington\u2019s disease patients. PLoS One 7(9):e46492","journal-title":"PLoS One"},{"issue":"11","key":"8145_CR43","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/glia.20838","volume":"57","author":"O Sagredo","year":"2009","unstructured":"Sagredo O, Gonzalez S, Aroyo I et al (2009) Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington\u2019s disease. Glia 57(11):1154\u20131167","journal-title":"Glia"},{"issue":"4","key":"8145_CR44","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1471-4159.2005.03074.x","volume":"93","author":"E Butovsky","year":"2005","unstructured":"Butovsky E, Juknat A, Goncharov I et al (2005) In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol. J Neurochem 93(4):802\u2013811","journal-title":"J Neurochem"},{"issue":"4","key":"8145_CR45","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00213-008-1333-2","volume":"202","author":"DC D\u2019Souza","year":"2009","unstructured":"D\u2019Souza DC, Pittman B, Perry E, Simen A (2009) Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology 202(4):569\u2013578","journal-title":"Psychopharmacology"},{"issue":"7","key":"8145_CR46","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","volume":"163","author":"L Petrocellis De","year":"2011","unstructured":"De Petrocellis L, Ligresti A, Moriello AS et al (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163(7):1479\u20131494","journal-title":"Br J Pharmacol"},{"issue":"1\u20132","key":"8145_CR47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/dta.1565","volume":"6","author":"D Thieme","year":"2014","unstructured":"Thieme D, Sachs H, Uhl M (2014) Proof of cannabis administration by sensitive detection of 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid in hair using selective methylation and application of liquid chromatography- tandem and multistage mass spectrometry. Drug Test Anal 6(1\u20132):112\u2013118","journal-title":"Drug Test Anal"},{"issue":"Pt 1","key":"8145_CR48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","volume":"134","author":"C Blazquez","year":"2011","unstructured":"Blazquez C, Chiarlone A, Sagredo O et al (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington\u2019s disease. Brain 134(Pt 1):119\u2013136","journal-title":"Brain"},{"issue":"9","key":"8145_CR49","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2967\/jnumed.110.077156","volume":"51","author":"K Laere Van","year":"2010","unstructured":"Van Laere K, Casteels C, Dhollander I et al (2010) Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med 51(9):1413\u20131417","journal-title":"J Nucl Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-016-8145-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-016-8145-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-016-8145-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T08:16:02Z","timestamp":1567844162000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-016-8145-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,9]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["8145"],"URL":"https:\/\/doi.org\/10.1007\/s00415-016-8145-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,9]]}}}